As burnout reaches epidemic levels, people are spending more on quality sleep products and services than ever before. These companies are positioned to benefit from this powerful shift in consumer priorities.
The intersection of technology and wellness is creating entirely new product categories. From sleep tracking wearables to smart beds, these innovations are transforming how we understand and improve our rest.
Sleep disorders affect millions globally, but breakthrough treatments are emerging. Companies developing solutions for conditions like sleep apnea and insomnia are tapping into a massive, underserved market.
The world is increasingly prioritizing wellness, with quality sleep and relaxation becoming essential purchases rather than luxuries. These companies are at the forefront of this shift, offering everything from smart mattresses and sleep tracking technology to medical devices and relaxation services.
This collection blends established consumer brands with innovative healthcare and technology companies. You'll find a mix of stable bedding manufacturers alongside cutting-edge medical device makers targeting sleep disorders and mental wellness—providing both defensive consumer stability and healthcare growth potential.
These companies were strategically selected to capture the full spectrum of the "Rest & Recharge" economy. From sleep diagnostics and therapeutics to comfort products and relaxation services, each company addresses a specific aspect of our growing need for better rest in an increasingly busy world.
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Processed market capitalisation breakdown for the 'Rest & Recharge' basket.
SNBR: $150.06M
PRPL: $93.72M
INSP: $2.45B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+146.20%
On average, analysts expect assets in this group to grow 146.2% over the next year.
10 of 13 assets in this group are rated Buy by professional analysts.
